IL2 and neoplasm: In addition, some studies have also explored the role of Zoledronate in adoptive cell transfer, and found that Zoledronate administration systemically or locally can enhance the anti-tumor activity of Vγ9Vδ2 T cells without additional IL-2 (53–55).